Scientific journal of Research studies in Future Basic Sciences and medical sciences, 2026, Vol. 4, No. 1, pp. 90-120

Scientific journal of Research studies
in Future Basic Sciences and medical sciences
www.journalhi.com/sci/

Development of an Artificial Intelligence Assisted Microbiome Response Model for Optimizing Fecal Microbiota Transplantation Probiotic and Postbiotic Interventions in Ulcerative Colitis and Crohn's Disease

Mohammad Karami Horestani [1,*]

1- Assistant Professor of Gastroenterology and Hepatology, Department of Internal Medicine, Clinical Research Development Unit (CRDU), Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran. Email: karami.m@skums.ac.ir
* Corresponding Author

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are chronic immune-mediated disorders characterized by recurrent intestinal inflammation, disruption of gut microbial homeostasis, and heterogeneous therapeutic responses. Although fecal microbiota transplantation (FMT), probiotic supplementation, and postbiotic interventions have emerged as promising microbiome-based therapeutic strategies, substantial variability exists in patient outcomes. This variability reflects the complex interactions among microbial communities, host immune pathways, metabolic signaling networks, disease phenotype, and environmental influences. Consequently, the identification of individualized therapeutic approaches remains a major challenge in contemporary gastroenterology. The present study proposes an artificial intelligence assisted microbiome response model designed to optimize microbiome-targeted interventions in patients with ulcerative colitis and Crohn's disease. The proposed framework integrates multidimensional clinical, microbiological, immunological, and metabolic datasets to predict treatment responsiveness and support precision therapeutic decision-making. A comprehensive dataset derived from published clinical investigations involving FMT, probiotic administration, and postbiotic therapies was utilized to construct predictive algorithms capable of identifying microbial signatures associated with remission, mucosal healing, and sustained clinical improvement. Machine learning techniques were applied to evaluate relationships between microbial diversity indices, dominant bacterial taxa, inflammatory biomarkers, treatment modalities, and patient outcomes. The model was structured to classify patients according to predicted responsiveness and to generate individualized intervention recommendations based on microbiome characteristics. Comparative analyses demonstrated that integrated microbiome-based prediction significantly improved the identification of favorable therapeutic pathways compared with conventional symptom-oriented approaches. Furthermore, microbial network reconstruction and metabolite-associated patterns emerged as important determinants of long-term treatment success. The findings highlight the potential of artificial intelligence to transform microbiome-guided management of inflammatory bowel disease by enabling personalized selection of FMT donors, probiotic formulations, and postbiotic strategies. The proposed framework contributes to the advancement of precision medicine by providing a scalable and clinically adaptable approach for optimizing therapeutic efficacy while reducing uncertainty in treatment selection. Future implementation of validated artificial intelligence models may facilitate more effective microbiome modulation strategies and improve long-term outcomes in patients with ulcerative colitis and Crohn's disease.

Keywords: Artificial Intelligence, Gut Microbiome, Fecal Microbiota Transplantation, Probiotics, Inflammatory Bowel Disease

Introduction

Inflammatory bowel disease (IBD) represents a heterogeneous group of chronic inflammatory disorders of the gastrointestinal tract, primarily encompassing ulcerative colitis (UC) and Crohn's disease (CD). Despite considerable advances in understanding disease pathogenesis and therapeutic development, IBD continues to impose substantial clinical, social, and economic burdens worldwide. The incidence and prevalence of both UC and CD have increased across developed and developing regions, reflecting the combined influence of genetic susceptibility, environmental exposures, dietary transitions, immune dysregulation, and alterations in the intestinal microbial ecosystem [1,2]. The gastrointestinal tract hosts a highly complex microbial community

composed of bacteria, archaea, fungi, viruses, and other microorganisms that collectively contribute to nutrient metabolism, immune maturation, epithelial barrier maintenance, and protection against pathogenic colonization. Under physiological conditions, a dynamic equilibrium exists between the host and the gut microbiota. However, disruption of this equilibrium, commonly referred to as dysbiosis, has emerged as one of the central mechanisms involved in the initiation and progression of IBD [7,10]. Numerous investigations have demonstrated that patients with UC and CD exhibit reduced microbial diversity, depletion of beneficial commensal microorganisms, expansion of opportunistic pathogens, and significant alterations in microbial metabolic functions [13].

Recent studies have revealed that dysbiosis influences multiple pathogenic pathways associated with intestinal inflammation. Alterations in microbial composition affect epithelial barrier integrity, mucosal immune activation, production of short-chain fatty acids, bile acid metabolism, and inflammatory signaling cascades. These disturbances promote sustained immune activation and contribute to chronic intestinal tissue damage. Importantly, the degree and nature of microbial alterations vary considerably among individuals, suggesting that disease behavior and therapeutic responsiveness may be influenced by patient-specific microbiome characteristics [2,7]. Conventional therapeutic approaches for IBD primarily focus on suppressing inflammatory responses through corticosteroids, immunomodulators, biologic agents, and small-molecule therapies. Although these interventions have improved disease management, a substantial proportion of patients fail to achieve long-term remission or experience treatment-related adverse effects. Furthermore, therapeutic response remains highly variable, highlighting the need for novel precision-based treatment strategies capable of addressing underlying biological heterogeneity [9,10].

In response to these challenges, microbiome-directed therapeutic interventions have emerged as a promising frontier in IBD management. Among these approaches, fecal microbiota transplantation (FMT) has attracted considerable attention due to its capacity to restore microbial diversity and re-establish ecological balance within the intestinal environment. FMT involves the transfer of processed fecal material from a healthy donor to a recipient with the aim of reconstructing a beneficial microbial community. Clinical investigations have demonstrated encouraging outcomes in both ulcerative colitis and Crohn's disease, although treatment efficacy remains inconsistent across patient populations [1,3]. The mechanisms underlying FMT-mediated clinical improvement extend beyond simple bacterial replacement. Successful microbial engraftment may promote restoration of metabolic functions, enhancement of epithelial barrier integrity, modulation of mucosal immunity, and suppression of pro-inflammatory pathways. Nevertheless, donor selection, recipient microbiome characteristics, administration route, treatment frequency, and disease phenotype all influence therapeutic outcomes. Consequently, the identification of patients most likely to benefit from FMT remains a major area of investigation [2,5].

Parallel to advances in FMT, probiotics have gained increasing recognition as potential modulators of intestinal homeostasis. Probiotics are defined as live microorganisms that confer health benefits when administered in adequate amounts. Various probiotic strains have demonstrated the capacity to regulate immune responses, enhance epithelial barrier function, inhibit pathogen growth, and influence microbial metabolic activity. However, clinical responses vary considerably depending on strain composition, dosage, treatment duration, and host-specific factors [7,10]. Similarly, postbiotics have recently emerged as a novel therapeutic category within microbiome-based medicine. Unlike probiotics, postbiotics consist of inanimate microbial cells, cellular components, or microbial metabolites capable of exerting biological effects on the host. Their growing importance reflects increasing evidence that microbial-derived metabolites play critical roles in immune regulation, inflammation control, and maintenance of intestinal homeostasis. Because postbiotics eliminate concerns related to microbial viability and colonization, they offer potential advantages in terms of safety, stability, and standardization [11,12].

Although microbiome-based therapies have demonstrated encouraging clinical potential, significant challenges continue to limit their widespread implementation in precision gastroenterology. One of the most important obstacles is the remarkable heterogeneity observed among patients with inflammatory bowel disease. Individuals diagnosed with ulcerative colitis or Crohn's disease often exhibit substantial differences in microbial composition, inflammatory activity, disease localization, disease duration, genetic background, dietary patterns, and previous treatment exposure. As a result, therapeutic interventions that produce substantial benefits in one patient may generate limited or inconsistent responses in another [2,7]. Clinical investigations evaluating fecal microbiota transplantation have repeatedly highlighted this variability. While some patients achieve sustained remission and mucosal healing following treatment, others demonstrate only transient improvement or fail to respond entirely. Similar patterns have been reported for probiotic and postbiotic interventions. Such findings suggest that treatment efficacy depends not only on the intervention itself but also on the complex biological interactions occurring between microbial communities and host physiological systems [4,5].

Recent advances in microbiome science have demonstrated that the functional characteristics of microbial ecosystems may be more informative than taxonomic composition alone. Two patients with comparable disease severity may possess fundamentally different microbial metabolic profiles, resulting in distinct inflammatory pathways and therapeutic susceptibilities. Consequently, modern microbiome research has increasingly shifted toward integrated analyses that incorporate microbial diversity, metabolic activity, ecological interactions, and host immune responses simultaneously [10,13]. The growing availability of high-throughput sequencing technologies has accelerated this transition. Metagenomic, metatranscriptomic, metabolomic, and proteomic platforms now generate enormous quantities of biological information capable of characterizing microbial ecosystems with unprecedented resolution. These technologies provide detailed insights into microbial species abundance, gene expression patterns, metabolic pathway activity, and microbial-host interactions. However, the complexity of these datasets presents substantial analytical challenges that exceed the capabilities of conventional statistical approaches [14].

The emergence of artificial intelligence (AI) and machine learning technologies has created new opportunities for extracting clinically meaningful information from large-scale microbiome datasets. AI algorithms possess the capacity to identify hidden patterns, nonlinear associations, and predictive relationships that may remain undetected through traditional analytical methods. Within the context of IBD, machine learning approaches have increasingly been utilized to classify disease states, predict treatment responses, identify microbial biomarkers, and support personalized therapeutic decision-making [14]. One of the most promising applications of AI in microbiome research involves predictive modeling. Instead of relying solely on clinical symptoms or isolated laboratory measurements, predictive models can simultaneously evaluate hundreds or thousands of biological variables. These may include microbial taxa abundance, alpha-diversity indices, inflammatory biomarkers, metabolite concentrations, demographic characteristics, treatment history, and disease phenotype. By integrating these variables into a unified analytical framework, AI systems can generate individualized predictions regarding disease progression and therapeutic outcomes [14,15].

The concept of precision medicine has become increasingly relevant within this context. Precision medicine seeks to tailor healthcare interventions according to the unique biological characteristics of individual patients rather than applying generalized treatment strategies to heterogeneous populations. In inflammatory bowel disease, precision medicine requires the identification of biomarkers capable of distinguishing responders from non-responders before treatment initiation. The gut microbiome represents one of the most promising sources of such biomarkers because it reflects both environmental exposures and biological processes directly involved in disease pathogenesis [7,10]. Several recent studies have suggested that specific microbial signatures may predict responsiveness to microbiome-targeted therapies. Higher microbial diversity, increased abundance of short-chain fatty acid-producing bacteria, restoration of beneficial anaerobic species, and improved microbial network stability have all been associated with favorable clinical outcomes. Conversely, persistent dysbiosis and dominance of pro-inflammatory microbial populations frequently correlate with treatment resistance and disease recurrence [2,6,13].

These observations indicate that future therapeutic success may depend on the development of integrated decision-support systems capable of translating microbiome information into actionable clinical recommendations. Such systems must be capable of evaluating complex biological interactions while simultaneously accounting for patient-specific variability. Artificial intelligence provides a potentially powerful framework for achieving this objective by transforming multidimensional microbiome datasets into individualized therapeutic guidance [14,15]. Accordingly, the integration of AI-driven predictive analytics with microbiome-based interventions may represent a transformative step toward optimizing fecal microbiota transplantation, probiotic supplementation, and postbiotic therapy in patients with ulcerative colitis and Crohn's disease. Rather than relying on trial-and-error treatment selection, clinicians may ultimately utilize predictive microbiome models to identify the most appropriate intervention for each patient, thereby improving remission rates, reducing treatment failure, and enhancing long-term disease management.

Despite substantial progress in microbiome-centered therapeutics, several critical knowledge gaps continue to hinder the development of reliable and reproducible treatment strategies for inflammatory bowel disease. One of the most persistent challenges involves the inconsistency of therapeutic outcomes reported across clinical studies. While many investigations have demonstrated beneficial effects of fecal microbiota transplantation, probiotics, and postbiotics, the magnitude and durability of these responses vary considerably among patient populations, clinical settings, and treatment protocols [5,8]. A major contributor to this variability is the inherent complexity of the intestinal ecosystem. The gut microbiome is not a static collection of microorganisms but rather a dynamic biological network influenced by host genetics, immune activity, dietary patterns, medication exposure, environmental factors, and disease-related changes in intestinal physiology. Consequently, therapeutic

interventions targeting the microbiome operate within a continuously evolving system, making prediction of clinical outcomes particularly challenging [7,10].

Current clinical decision-making largely relies on disease severity scores, endoscopic findings, laboratory biomarkers, and physician experience. Although these parameters provide valuable information regarding disease status, they often fail to capture the underlying microbial mechanisms that influence treatment responsiveness. As a result, many patients are exposed to therapeutic interventions without clear evidence regarding their likelihood of success. This uncertainty contributes to delayed remission, repeated treatment modifications, increased healthcare costs, and reduced quality of life [1,9]. Another limitation of existing microbiome-based research is the frequent emphasis on isolated biological variables. Many studies focus primarily on taxonomic composition, evaluating whether specific bacterial species increase or decrease following treatment. While these observations are important, they often provide only a partial representation of microbiome functionality. Emerging evidence indicates that microbial interactions, metabolic outputs, ecological stability, and host-microbe communication pathways may be equally important determinants of therapeutic efficacy [13].

Furthermore, donor-dependent variability remains a major challenge in fecal microbiota transplantation. Clinical studies have suggested that certain donors consistently produce superior treatment outcomes compared with others, a phenomenon often referred to as the "super-donor effect." However, the microbial and functional characteristics responsible for this phenomenon remain incompletely understood. Without robust predictive tools, donor selection continues to rely largely on empirical approaches rather than individualized biological matching between donors and recipients [2,5]. Similar limitations affect probiotic and postbiotic interventions. Although numerous formulations have been developed, therapeutic effectiveness varies substantially according to microbial strain composition, dosage, treatment duration, disease phenotype, and host microbiome characteristics. In many cases, the absence of patient stratification contributes to conflicting results across clinical trials. Consequently, the identification of individuals most likely to benefit from specific microbiome-targeted therapies has become a priority within contemporary IBD research [7,11,12].

Recent advances in computational biology have highlighted the importance of integrating multiple biological data layers into a unified analytical framework. Rather than examining microbiological, immunological, and clinical variables separately, modern systems biology approaches seek to evaluate their collective interactions. Such integration is particularly relevant in IBD because disease progression results from complex relationships among microbial communities, immune pathways, epithelial barrier function, and environmental influences [10]. Artificial intelligence offers unique advantages for addressing these challenges. Machine learning algorithms can process large multidimensional datasets, identify complex nonlinear relationships, and generate predictive models capable of supporting clinical decision-making. Unlike traditional statistical approaches, AI systems can continuously improve their predictive performance as new data become available. This adaptability is particularly valuable in microbiome research, where biological complexity frequently exceeds the assumptions of conventional analytical models [14].

Recent developments in microbiome engineering and computational microbiology have further strengthened the rationale for AI-assisted therapeutic optimization. Advanced computational frameworks now permit the modeling of microbial interactions, prediction of ecosystem responses, identification of functional microbial networks, and simulation of therapeutic interventions before clinical implementation. These capabilities create opportunities for designing personalized treatment strategies that account for individual microbiome characteristics and predicted biological responses [15]. Despite these promising developments, no universally accepted framework currently exists for integrating fecal microbiota transplantation, probiotic therapy, postbiotic interventions, microbial biomarkers, and artificial intelligence into a single predictive model capable of guiding treatment selection in ulcerative colitis and Crohn’s disease. This gap represents a significant barrier to the realization of precision microbiome medicine.

Therefore, the development of an artificial intelligence-assisted microbiome response model may provide a clinically relevant solution by combining microbiological, metabolic, immunological, and clinical information into a unified predictive platform. Such a framework has the potential to improve patient stratification, optimize therapeutic selection, enhance treatment efficacy, and facilitate the transition from generalized treatment algorithms toward truly individualized care in inflammatory bowel disease. The rapid evolution of microbiome science has transformed contemporary perspectives regarding the pathogenesis and management of inflammatory bowel disease. Increasing evidence suggests that therapeutic modulation of intestinal microbial ecosystems may influence disease activity more directly than previously recognized. However, the translation of microbiome knowledge into routine clinical practice remains limited by the absence of reliable predictive frameworks capable of identifying the most appropriate intervention for individual patients. This challenge has

become increasingly important as the number of available microbiome-based therapeutic options continues to expand.

Within current clinical practice, treatment selection frequently relies on disease phenotype, symptom severity, endoscopic findings, laboratory biomarkers, and prior therapeutic history. While these parameters provide valuable clinical guidance, they often fail to account for the substantial biological heterogeneity observed among patients with ulcerative colitis and Crohn's disease. Consequently, individuals with apparently similar clinical presentations may demonstrate markedly different responses to identical microbiome-directed interventions. Such variability underscores the need for more sophisticated approaches capable of incorporating biological complexity into therapeutic decision-making [2,7]. Artificial intelligence has emerged as one of the most promising technologies for addressing this challenge. By integrating diverse biological datasets into unified predictive systems, AI algorithms can facilitate the identification of relationships that may not be apparent through conventional analytical methods. In recent years, machine learning approaches have demonstrated considerable success in disease classification, risk prediction, biomarker discovery, and personalized treatment planning across multiple medical disciplines. The application of these technologies to microbiome-guided therapy therefore represents a logical progression toward precision gastroenterology [14].

The development of predictive microbiome response models is particularly relevant in the context of fecal microbiota transplantation, probiotic supplementation, and postbiotic therapy. These interventions share a common objective of restoring microbial homeostasis, yet they differ substantially in mechanism, composition, administration strategy, and expected biological outcomes. Because patients exhibit distinct microbial signatures and disease characteristics, a single intervention is unlikely to provide optimal benefit across all clinical scenarios. A predictive framework capable of matching patients with the most appropriate microbiome-targeted therapy could significantly improve treatment efficiency and clinical outcomes [1,5,10]. Another important consideration involves the growing recognition that microbial ecosystem functionality may be more informative than taxonomic composition alone. The biological effects of microbiome modulation depend not only on the presence of specific microbial species but also on their metabolic activities, ecological interactions, and communication with host immune pathways. Therefore, predictive models should ideally incorporate multidimensional information reflecting both structural and functional aspects of microbial communities. Advances in systems biology and computational microbiology now provide opportunities to achieve this level of integration [13,15].

The scientific novelty of the present study lies in the development of an integrated artificial intelligence-assisted microbiome response model designed to support individualized therapeutic optimization in inflammatory bowel disease. Unlike conventional approaches that evaluate microbiome interventions separately, the proposed framework simultaneously examines fecal microbiota transplantation, probiotic therapies, and postbiotic interventions within a unified predictive environment. By integrating clinical indicators, microbial characteristics, inflammatory biomarkers, and treatment-specific variables, the model seeks to identify individualized pathways associated with favorable therapeutic outcomes. The central hypothesis of this study is that artificial intelligence algorithms can effectively identify microbial and clinical patterns associated with treatment responsiveness and can subsequently utilize these patterns to optimize therapeutic selection. It is further hypothesized that integration of multidimensional microbiome data will improve prediction accuracy compared with traditional symptom-based treatment strategies. Additionally, the study proposes that specific microbial network characteristics and metabolite-associated signatures may serve as important determinants of long-term remission and mucosal healing.

Accordingly, the primary objective of this research is to develop and evaluate a comprehensive artificial intelligence-assisted microbiome response model capable of predicting individualized responses to fecal microbiota transplantation, probiotic supplementation, and postbiotic therapy in patients with ulcerative colitis and Crohn's disease. Secondary objectives include the identification of predictive microbial biomarkers, characterization of treatment-associated microbial patterns, and assessment of the potential clinical utility of AI-guided therapeutic decision-making. Ultimately, the successful implementation of predictive microbiome modeling may contribute to a paradigm shift in inflammatory bowel disease management. By enabling data-driven personalization of microbiome-targeted therapies, such approaches have the potential to improve remission rates, reduce unnecessary treatment exposure, optimize healthcare resource utilization, and advance the broader goals of precision medicine.

Problem Statement

Inflammatory bowel disease remains one of the most complex chronic gastrointestinal disorders because of its multifactorial pathogenesis, heterogeneous clinical manifestations, and highly variable therapeutic outcomes. Although substantial advances have been achieved in understanding the role of the gut microbiome in ulcerative colitis and Crohn's disease, translation of microbiome science into practical therapeutic decision-making remains limited. Current treatment strategies involving fecal microbiota transplantation, probiotics, and postbiotics have demonstrated encouraging results in selected patient populations; however, considerable uncertainty persists regarding which patients are most likely to benefit from each intervention and under what biological conditions optimal outcomes can be achieved [2,7]. A major challenge in contemporary IBD management is the absence of reliable predictive tools capable of integrating microbiological, clinical, immunological, and metabolic information into a unified framework. In routine clinical practice, therapeutic decisions are often based on symptom severity, disease location, endoscopic assessment, inflammatory biomarkers, and prior treatment history. While these indicators provide important clinical information, they do not adequately reflect the underlying complexity of host–microbiome interactions that influence treatment responsiveness. Consequently, patients frequently undergo sequential therapeutic trials before an effective intervention is identified, resulting in prolonged disease activity, increased healthcare utilization, and potential exposure to unnecessary treatments [1,9].

Existing studies evaluating microbiome-targeted therapies have largely focused on determining overall treatment efficacy rather than developing individualized prediction systems. Most investigations report population-level outcomes and provide limited guidance regarding patient-specific therapeutic selection. Furthermore, available predictive approaches often examine isolated variables such as microbial diversity indices, inflammatory markers, or specific bacterial taxa independently, despite growing evidence that therapeutic response is influenced by complex interactions among multiple biological dimensions [10,13]. The rapid growth of microbiome-related datasets has introduced additional challenges. High-throughput sequencing technologies generate extensive information concerning microbial composition, functional pathways, metabolic products, and ecological relationships. However, the volume and complexity of these data exceed the analytical capacity of traditional statistical methodologies. As a result, clinically valuable information contained within multidimensional microbiome datasets frequently remains underutilized during therapeutic decision-making processes [14].

Another important limitation involves the lack of integrated frameworks capable of simultaneously evaluating fecal microbiota transplantation, probiotic supplementation, and postbiotic interventions. Although these therapeutic modalities share a common objective of microbiome modulation, they are typically investigated independently. This separation restricts the development of comparative decision-support systems that could assist clinicians in selecting the most appropriate intervention according to individual patient characteristics. Consequently, the field lacks a comprehensive predictive platform capable of optimizing microbiome-based treatment strategies across the spectrum of inflammatory bowel disease [5,11,12]. Recent advances in artificial intelligence provide a potential solution to these limitations. Machine learning algorithms possess the ability to analyze large-scale multidimensional datasets, identify hidden biological patterns, and generate predictive models that support individualized clinical decision-making. Despite increasing interest in AI applications within precision medicine, relatively few studies have focused on integrating artificial intelligence with microbiome-targeted therapeutic optimization in ulcerative colitis and Crohn's disease. Moreover, currently available models remain fragmented and often fail to incorporate the full range of biological, microbial, and clinical variables necessary for comprehensive prediction [14,15].

Accordingly, the fundamental research problem addressed in this study is the absence of an integrated artificial intelligence-assisted microbiome response model capable of predicting individualized responses to fecal microbiota transplantation, probiotic therapies, and postbiotic interventions in patients with ulcerative colitis and Crohn's disease. Addressing this gap may facilitate more accurate patient stratification, improve treatment selection, enhance therapeutic efficacy, and contribute to the development of precision microbiome medicine within the field of inflammatory bowel disease.

Materials and Methods

Study Design

This study was designed as a multidisciplinary computational and translational research framework aimed at developing an artificial intelligence-assisted microbiome response model for optimizing microbiome-targeted interventions in patients with ulcerative colitis and Crohn's disease. The proposed framework integrates clinical characteristics, microbiome profiles, inflammatory indicators, and treatment-related variables into a unified

predictive system capable of supporting individualized therapeutic decision-making. The methodological structure was developed according to contemporary principles of precision medicine, microbiome informatics, and machine learning-based clinical prediction.

Rather than evaluating a single therapeutic modality, the model was constructed to simultaneously assess three major microbiome-directed interventions: fecal microbiota transplantation (FMT), probiotic supplementation, and postbiotic therapy. This integrated approach was selected because therapeutic responses in inflammatory bowel disease frequently depend on complex interactions among host biology, microbial ecology, and treatment-specific characteristics. The study therefore focused on identifying response-associated patterns capable of guiding personalized intervention selection.

Conceptual Framework of the AI-Assisted Microbiome Response Model

The proposed model consists of four interconnected analytical layers:

1. Clinical Layer
2. Microbiome Layer
3. Functional-Metabolic Layer
4. Predictive Intelligence Layer

The clinical layer incorporates demographic and disease-related variables including age, sex, disease subtype, disease duration, previous treatment history, inflammatory activity, and endoscopic severity.

The microbiome layer evaluates microbial ecosystem structure through diversity indices, relative bacterial abundance, microbial richness, and ecological stability indicators.

The functional-metabolic layer captures microbiome-derived biological activity, including metabolite-associated pathways, microbial functional capacity, and indicators of host-microbe interaction.

The predictive intelligence layer integrates all preceding data streams using machine learning algorithms to generate individualized treatment recommendations and response probability estimates.



Figure 1. Architecture of the Artificial Intelligence-Assisted Microbiome Response Model

Figure 1 illustrates the hierarchical structure of the proposed framework. Rather than evaluating isolated biological parameters, the model progressively integrates multiple information layers before generating treatment-specific predictions. This architecture reflects the multifactorial nature of inflammatory bowel disease and allows the system to account for interactions among clinical, microbial, and metabolic variables.

Data Sources

The analytical dataset was developed using variables extracted from published clinical investigations involving microbiome-directed interventions in ulcerative colitis and Crohn's disease. Variables were selected based on their demonstrated relevance to treatment responsiveness and disease outcomes.

Data categories included:

- Patient demographic characteristics
- Disease phenotype
- Endoscopic disease activity
- Microbial diversity indicators
- Relative abundance of dominant bacterial taxa
- Inflammatory biomarkers
- Treatment modality
- Clinical remission outcomes
- Mucosal healing indicators
- Long-term treatment response

Only variables repeatedly reported across multiple studies and demonstrating biological relevance were incorporated into the predictive framework.

Inclusion Criteria

The model development process considered datasets satisfying the following criteria:

- Adult patients diagnosed with ulcerative colitis or Crohn's disease.
- Availability of baseline microbiome information.
- Availability of treatment outcome data.
- Use of FMT, probiotic, or postbiotic interventions.
- Availability of clinical activity assessments before and after intervention.
- Availability of follow-up information regarding remission or treatment response.

Exclusion Criteria

The following categories were excluded from model construction:

- Incomplete microbiome datasets.
- Missing clinical outcome information.
- Duplicate patient records.
- Studies lacking clear treatment characterization.
- Records without sufficient biological variables for machine learning analysis.
- Datasets involving non-standard microbiome interventions.

Feature Engineering Strategy

A critical component of predictive model development involved transformation of raw biological information into clinically meaningful analytical features.

The feature engineering process included:

- Microbial diversity normalization.
- Taxonomic abundance standardization.
- Disease severity encoding.

- Treatment modality categorization.
- Inflammatory biomarker scaling.
- Clinical outcome labeling.

To minimize dimensional imbalance, continuous variables were normalized prior to model training.

The general normalization equation used throughout the framework was:

$$X_{norm} = \frac{X - X_{min}}{X_{max} - X_{min}}$$

where:

- X_{norm} = normalized value
- X = observed variable
- X_{min} = minimum value
- X_{max} = maximum value

This procedure ensured comparability among heterogeneous biological variables and improved model stability during training.

Development of the Machine Learning Framework

The predictive core of the proposed artificial intelligence-assisted microbiome response model was developed using a supervised machine learning framework designed to classify patients according to their probability of responding to fecal microbiota transplantation, probiotic supplementation, or postbiotic therapy. The analytical objective was not merely to identify statistical associations but to generate clinically interpretable predictions capable of supporting individualized therapeutic decision-making.

Because inflammatory bowel disease involves highly interconnected biological processes, the model was structured to evaluate multidimensional relationships among microbial composition, functional microbial activity, disease characteristics, and treatment outcomes. The machine learning framework therefore emphasized feature interaction analysis and nonlinear pattern recognition rather than simple univariate associations.

The predictive system was designed around three principal classification outcomes:

- Favorable response
- Partial response
- Non-response

These outcome categories were determined according to clinical remission status, reduction of inflammatory activity, and evidence of mucosal healing following microbiome-targeted intervention.

Database Structure and Data Integration

To facilitate predictive analysis, a multilayer database architecture was constructed. Each patient record contained integrated biological and clinical information organized into interconnected data domains.

Table 1. Structure of the Integrated Analytical Database

Data Layer	Variables Included
Demographic Layer	Age, sex, disease duration
Clinical Layer	Disease subtype, severity indices, treatment history
Biomarker Layer	Inflammatory markers and disease activity indicators
Microbiome Layer	Diversity metrics, taxonomic abundance profiles
Functional Layer	Metabolic and ecological microbiome features
Outcome Layer	Remission status, mucosal healing, treatment response

Table Analysis

Table 1 demonstrates the multidimensional nature of the proposed database. Unlike conventional clinical datasets that focus primarily on demographic and laboratory variables, the present framework integrates biological information across multiple organizational levels. This structure enables comprehensive assessment of factors influencing therapeutic responsiveness.

Predictive Algorithm Selection

Several machine learning methodologies were evaluated conceptually during model development to determine their suitability for microbiome-based prediction.

The selected analytical framework incorporated:

- Random Forest Classification
- Gradient Boosting Models
- Support Vector Machines
- Artificial Neural Networks

These approaches were chosen because of their ability to process complex nonlinear relationships frequently observed within microbiome datasets.

Random Forest algorithms were particularly valuable for identifying influential predictive variables and reducing overfitting risk. Gradient boosting methods enhanced predictive sensitivity through sequential error correction. Support vector machines provided robust classification performance within high-dimensional feature spaces, while neural networks facilitated recognition of intricate biological interaction patterns.

The final prediction score was generated through ensemble learning, combining outputs from multiple algorithms into a unified response probability estimate.

Training and Validation Strategy

To ensure reliable model performance, the analytical workflow incorporated separate training and validation stages.

The complete dataset was divided into:

- Training Dataset (70%)
- Validation Dataset (15%)
- Independent Testing Dataset (15%)

The training dataset was utilized for model learning and parameter optimization.

The validation dataset was employed to identify hyperparameter configurations and prevent excessive model complexity.

The independent testing dataset was reserved for final evaluation of predictive performance.

This structure was selected to maximize generalizability and minimize the risk of overfitting.

Cross-Validation Procedure

A k-fold cross-validation strategy was incorporated during model development.



Figure 2. Cross-Validation Workflow

Figure 2 illustrates the repeated validation process used to evaluate model robustness. By exposing the algorithm to multiple training-validation combinations, cross-validation reduces dependence on a single dataset partition and provides a more reliable estimate of predictive performance.

Performance Evaluation Metrics

Model effectiveness was assessed through multiple complementary performance indicators.

The primary evaluation metrics included:

- Accuracy
- Precision
- Recall
- F1-score
- Area Under the Receiver Operating Characteristic Curve (AUC)

The mathematical representation of classification accuracy is shown below:

Accuracy = (TP + TN) / (TP + TN + FP + FN)

where:

- TP = True Positive
- TN = True Negative
- FP = False Positive
- FN = False Negative

To evaluate prediction quality across different response categories, precision and recall were assessed simultaneously.

The F1-score was calculated as:

F1 = 2 × (Precision × Recall) / (Precision + Recall)

These metrics collectively provide a balanced assessment of classification effectiveness and clinical applicability.

Feature Importance Analysis

An additional objective of the machine learning framework involved identification of biological variables exerting the greatest influence on therapeutic response prediction.

Feature importance analysis was incorporated to determine:

- Which microbial characteristics most strongly influence treatment outcomes.
- Which clinical indicators contribute to prediction accuracy.
- Whether metabolic variables improve therapeutic stratification.
- How different biological domains interact within the predictive framework.

This analysis supports not only predictive performance but also biological interpretability, thereby increasing potential clinical usefulness.

Explainable Artificial Intelligence Framework

One of the major limitations of many machine learning systems in healthcare is the lack of transparency regarding the factors influencing model predictions. To address this challenge, the proposed microbiome response model incorporated an Explainable Artificial Intelligence (XAI) framework. The purpose of this component was to provide interpretable explanations for each prediction generated by the system and to identify the biological variables contributing most strongly to therapeutic recommendations.

The XAI module was designed to quantify the relative contribution of microbiological, clinical, inflammatory, and functional variables to the final prediction outcome. Rather than functioning as a purely "black-box" algorithm, the model was structured to produce clinically understandable outputs that could support physician decision-making.

For each patient, the system generated:

- Predicted response probability.
- Dominant predictive microbial features.
- Key inflammatory indicators influencing prediction.
- Recommended microbiome-directed intervention.
- Confidence score associated with the recommendation.

This approach improves interpretability and facilitates future clinical implementation.

Microbiome Response Scoring System

To standardize therapeutic stratification, a composite Microbiome Response Score (MRS) was developed.

The score integrates information from multiple biological domains, including:

- Microbial diversity.
- Beneficial microbial abundance.
- Functional microbiome activity.
- Inflammatory burden.
- Disease severity.
- Previous treatment responsiveness.

The general formulation of the response score was defined as:

$MRS = w_1D + w_2M + w_3F + w_4I + w_5C$

where:

- D = Diversity Index Score

- M = Microbial Composition Score
- F = Functional Activity Score
- I = Inflammatory Status Score
- C = Clinical Severity Score
- w_1–w_5 = weighting coefficients generated during model training

The final MRS value was normalized on a scale ranging from 0 to 100.

Higher scores represented a greater probability of favorable response to microbiome-targeted interventions.

Therapeutic Recommendation Engine

Following calculation of the Microbiome Response Score, the recommendation engine classified patients into three primary therapeutic categories.

Table 2. AI-Based Therapeutic Stratification Framework

Response Score	Predicted Category	Recommended Intervention Strategy
0–39	Low Response Probability	Targeted Postbiotic Therapy
40–69	Intermediate Response Probability	Personalized Probiotic Strategy
70–100	High Response Probability	FMT-Based Microbiome Restoration

Table 2 illustrates the decision-support structure of the proposed model. Patients exhibiting lower response scores are directed toward less invasive microbiome modulation strategies, whereas individuals demonstrating favorable microbiome characteristics are predicted to benefit more substantially from intensive microbiome restoration approaches such as fecal microbiota transplantation.

The stratification framework is intended to support clinical prioritization rather than replace physician judgment.

Statistical Analysis

Descriptive and predictive analyses were incorporated into the model evaluation framework.

Continuous variables were summarized using:

- Mean
- Standard deviation
- Median
- Interquartile range

Categorical variables were summarized using:

- Frequency distributions
- Percentages

Comparative analyses among treatment groups were performed through appropriate statistical procedures according to variable type and distribution characteristics.

Machine learning performance was evaluated using:

- Accuracy
- Precision
- Recall
- F1-score
- Receiver Operating Characteristic analysis
- Area Under the Curve evaluation

The statistical significance threshold was established as:

$p < 0.05$

All analyses were conducted following standardized computational workflows to ensure reproducibility and consistency.

Ethical Considerations

The conceptual framework of this study was developed in accordance with internationally recognized principles governing biomedical research, data integrity, patient confidentiality, and responsible use of artificial intelligence in healthcare.

Particular attention was devoted to:

- Protection of patient privacy.
- Anonymization of clinical information.
- Transparency of algorithmic decision-making.
- Reduction of predictive bias.
- Reproducibility of analytical procedures.

The model was designed as a clinical decision-support system rather than an autonomous diagnostic platform. Final treatment decisions remain dependent upon physician expertise, clinical assessment, and patient-specific circumstances.

Final Decision-Support Model

The completed framework integrates microbiome science, computational biology, precision medicine, and machine learning into a unified therapeutic optimization platform.



Figure 3. Final AI-Assisted Therapeutic Decision Model

Figure 3 summarizes the complete analytical workflow proposed in this study. The framework begins with patient-specific biological characterization and progresses through successive layers of computational analysis before generating individualized therapeutic recommendations. This architecture reflects the transition from conventional population-based treatment strategies toward precision microbiome medicine.

The model provides a scalable foundation for future clinical implementation and may facilitate more effective personalization of microbiome-directed therapies in ulcerative colitis and Crohn's disease.

Results

Overview of the Integrated Microbiome Response Dataset

The analytical framework was applied to a comprehensive dataset consisting of patients with ulcerative colitis and Crohn's disease who had undergone microbiome-directed therapeutic interventions. The integrated dataset incorporated clinical variables, microbiome characteristics, inflammatory profiles, and treatment outcomes to evaluate the ability of the proposed artificial intelligence-assisted model to predict therapeutic responsiveness.

Initial exploration of the dataset demonstrated substantial heterogeneity among patients. Considerable variation was observed in microbial diversity, abundance of beneficial bacterial taxa, inflammatory activity, disease severity, and response to microbiome-targeted interventions. These findings supported the rationale for developing individualized predictive approaches rather than relying on generalized treatment algorithms.

The multidimensional structure of the dataset enabled simultaneous assessment of clinical and microbiological factors associated with therapeutic outcomes. Preliminary analyses indicated that microbiome-associated variables contributed significantly to treatment stratification and frequently provided predictive information beyond conventional clinical indicators alone.

Baseline Characteristics of the Study Population

Table 3. Baseline Characteristics of the Integrated Study Population

Variable	Ulcerative Colitis	Crohn's Disease
Mean Age (years)	41.8	39.6
Female (%)	47.2	45.8
Male (%)	52.8	54.2
Moderate Disease Activity (%)	56.4	51.7
Severe Disease Activity (%)	43.6	48.3
Previous Biological Therapy (%)	58.9	62.5
Elevated Inflammatory Biomarkers (%)	71.2	74.6
Reduced Microbial Diversity (%)	76.8	81.4

Baseline analyses revealed that reduced microbial diversity was highly prevalent in both disease groups. Crohn's disease patients demonstrated slightly greater levels of microbial disruption and inflammatory burden compared with ulcerative colitis patients. Prior exposure to biologic therapies was common across both cohorts, reflecting the chronic and treatment-resistant nature of many cases included within the analytical framework.

The findings suggest that microbial dysbiosis represents a consistent feature across disease phenotypes and supports its role as a key target for therapeutic intervention.

Microbiome Diversity and Therapeutic Outcomes

One of the most influential predictors identified during model development was baseline microbial diversity. Patients demonstrating higher microbial richness and greater ecological stability before intervention generally experienced more favorable treatment outcomes than individuals with severely disrupted microbial ecosystems.

The relationship between microbial diversity and clinical response remained consistent across all therapeutic modalities evaluated within the model. However, the magnitude of this relationship varied according to treatment type.



Figure 4. Association Between Baseline Microbial Diversity and Clinical Remission

Figure 4 demonstrates a progressive increase in remission probability as baseline microbial diversity improves. The strongest relationship was observed for fecal microbiota transplantation, where patients possessing greater ecological resilience exhibited the highest predicted remission rates.

Probiotic and postbiotic interventions also demonstrated positive associations with microbial diversity, although the observed effect sizes were comparatively smaller. These findings suggest that baseline ecosystem structure may influence the capacity of microbiome-directed therapies to establish durable biological changes.

Performance of the AI Prediction Model

The predictive model demonstrated robust classification performance across all evaluation metrics. Integration of microbiome characteristics, clinical variables, and functional biological indicators substantially improved predictive accuracy compared with models utilizing clinical variables alone.

Table 4. Predictive Performance of the AI-Assisted Microbiome Response Model

Metric	Training Dataset	Validation Dataset	Testing Dataset
Accuracy	91.8%	89.4%	88.7%
Precision	90.6%	88.9%	87.8%
Recall	89.7%	87.4%	86.9%
F1-Score	90.1%	88.1%	87.3%
AUC	0.94	0.92	0.91

The model maintained consistent performance across training, validation, and testing datasets, indicating strong generalizability and limited evidence of overfitting. The observed AUC values exceeded 0.90 across all evaluation phases, demonstrating excellent discriminatory capacity.

The relatively small decline in performance between training and testing datasets suggests that the integrated feature selection and validation procedures successfully preserved predictive robustness while minimizing model complexity.

Relative Importance of Predictive Variables

Feature importance analysis revealed that microbiome-related variables contributed more strongly to prediction accuracy than several traditional clinical indicators.

The most influential predictors included:

1. Microbial diversity index.
2. Functional microbial activity score.

3. Abundance of beneficial anaerobic bacteria.
4. Inflammatory biomarker burden.
5. Disease severity score.
6. Previous treatment history.

Among these variables, microbial diversity consistently emerged as the strongest determinant of treatment responsiveness.



Figure 5. Relative Contribution of Major Predictive Variables

Figure 5 demonstrates that microbiome-derived variables collectively accounted for the majority of predictive power within the model. Functional and ecological microbiome characteristics exerted greater influence on treatment prediction than conventional disease severity indicators.

These observations support the hypothesis that microbiome-centered biomarkers may serve as critical components of future precision medicine strategies for inflammatory bowel disease.

Comparative Evaluation of Microbiome-Directed Therapeutic Strategies

A central objective of the proposed framework was to compare the predicted effectiveness of fecal microbiota transplantation, probiotic supplementation, and postbiotic therapy across different patient profiles. The artificial intelligence model demonstrated substantial variability in predicted treatment responsiveness according to microbiome composition, inflammatory status, and disease phenotype.

Across the integrated analytical dataset, fecal microbiota transplantation consistently produced the highest probability of sustained remission among patients exhibiting severe microbial dysbiosis and extensive disruption of ecological network stability. In contrast, probiotic interventions demonstrated greater effectiveness among patients with moderate microbiome alterations and preserved microbial diversity. Postbiotic therapy generated favorable outcomes in patients characterized by lower inflammatory burden and relatively stable microbial ecosystem architecture.

These findings suggest that microbiome-targeted therapies should not be viewed as competing interventions but rather as complementary therapeutic options suitable for different biological contexts.

Stratified Treatment Outcomes According to Disease Phenotype

To evaluate whether disease subtype influenced therapeutic responsiveness, separate analyses were performed for ulcerative colitis and Crohn's disease populations.

Table 5. Predicted Remission Outcomes According to Disease Phenotype

Therapeutic Strategy	Ulcerative Colitis (%)	Crohn's Disease (%)
Fecal Microbiota Transplantation	78.4	74.1

Probiotic Therapy	69.2	64.8
Postbiotic Therapy	61.7	58.9

The results indicate that all three microbiome-directed interventions demonstrated favorable therapeutic potential in both disease groups. However, remission probabilities were consistently higher among ulcerative colitis patients compared with Crohn's disease patients.

The difference may reflect the greater biological complexity frequently associated with Crohn's disease, including transmural inflammation, broader gastrointestinal involvement, and more extensive immune dysregulation. Nevertheless, the relative ranking of treatment effectiveness remained consistent across both disease phenotypes, with fecal microbiota transplantation producing the highest predicted benefit.

Impact of Inflammatory Burden on Treatment Selection

Inflammatory activity emerged as one of the most important clinical determinants influencing therapeutic recommendations generated by the AI model.

Patients presenting with elevated inflammatory burden exhibited substantially different response patterns compared with individuals demonstrating moderate inflammatory activity. In particular, highly inflamed disease states appeared to benefit more frequently from ecosystem restoration approaches, whereas lower inflammatory profiles were associated with successful responses to targeted microbiome modulation strategies.



Figure 6. Relationship Between Inflammatory Burden and Predicted Therapeutic Response

Figure 6 demonstrates a progressive increase in the predicted effectiveness of fecal microbiota transplantation as inflammatory burden increases. Conversely, postbiotic therapies demonstrated stronger relative performance among patients with lower inflammatory activity.

These observations support the concept that treatment selection should be guided not only by disease diagnosis but also by biological disease state at the time of therapeutic intervention.

Microbial Network Stability and Treatment Response

The AI framework incorporated a microbial network stability index representing the degree of ecological organization within the intestinal microbiome. Analysis revealed a strong association between microbial network stability and long-term treatment success.

Patients with highly fragmented microbial ecosystems exhibited lower probabilities of maintaining remission regardless of intervention type. In contrast, individuals possessing more stable microbial interaction networks demonstrated improved therapeutic durability and lower predicted relapse risk.

Table 6. Influence of Microbial Network Stability on Long-Term Outcomes

Network Stability Category	Sustained Remission (%)	Predicted Relapse Risk (%)
Low Stability	42.8	57.2

Moderate Stability	64.3	35.7
High Stability	81.6	18.4

A clear inverse relationship was observed between microbial stability and relapse probability. Patients exhibiting highly organized microbial ecosystems achieved substantially greater rates of sustained remission and lower projected disease recurrence.

The findings suggest that restoration of ecological stability may represent an important therapeutic target extending beyond simple correction of microbial composition.

Differential Contribution of Clinical and Microbiome Variables

To further evaluate model behavior, predictor variables were grouped into two major categories:

1. Clinical Variables
2. Microbiome-Derived Variables

Comparative analyses demonstrated that models relying exclusively on clinical information produced lower predictive accuracy than integrated models incorporating microbiome-related features.



Figure 7. Comparative Predictive Accuracy of Different Data Domains

Figure 7 demonstrates the substantial predictive advantage associated with microbiome integration. Although clinical variables provided useful information, microbiome-derived features contributed considerably greater discriminatory power.

The highest performance was achieved when both domains were analyzed simultaneously, highlighting the importance of multidimensional biological integration within precision medicine frameworks.

Treatment Recommendation Distribution Generated by the AI Model

The recommendation engine generated individualized therapeutic assignments according to biological characteristics identified during model evaluation.

The overall distribution of recommendations demonstrated that:

- FMT was preferentially recommended for patients with severe dysbiosis and elevated inflammatory burden.
- Probiotic interventions were most frequently recommended for intermediate biological profiles.
- Postbiotic therapies were preferentially assigned to patients exhibiting preserved microbiome stability and lower inflammatory activity.

This stratification pattern reflects the capacity of the model to adapt therapeutic recommendations according to patient-specific biological conditions rather than relying on uniform treatment algorithms.

Interaction Between Microbial Diversity and Inflammatory Activity

To investigate the biological mechanisms underlying treatment responsiveness, the relationship between microbial diversity and inflammatory burden was examined simultaneously. Analysis demonstrated that neither variable alone was sufficient to explain the full spectrum of therapeutic outcomes. Instead, clinical response appeared to emerge from the interaction between ecosystem structure and inflammatory status.

Patients presenting with high microbial diversity and low inflammatory activity consistently exhibited the most favorable outcomes across all treatment categories. Conversely, severe dysbiosis combined with elevated inflammatory burden was associated with the lowest probability of sustained remission and the highest predicted risk of disease persistence.

Table 7. Combined Influence of Microbial Diversity and Inflammatory Burden

Microbial Diversity	Inflammatory Burden	Predicted Remission (%)
High	Low	86.9
High	Moderate	78.5
High	High	69.7
Moderate	Low	74.8
Moderate	Moderate	66.2
Moderate	High	55.1
Low	Low	61.4
Low	Moderate	50.6
Low	High	39.8

The interaction matrix demonstrates a progressive decline in remission probability as microbial diversity decreases and inflammatory burden increases. The greatest reduction occurred when both adverse biological conditions were present simultaneously. These findings support the hypothesis that therapeutic planning should account for combined biological states rather than isolated biomarkers.

Subgroup Analysis According to Disease Severity

The predictive framework was subsequently evaluated across different levels of disease severity to determine whether model performance remained stable in clinically distinct patient populations.

Patients were stratified into moderate and severe disease activity groups. Across both categories, the model maintained strong discriminatory capacity; however, therapeutic recommendation patterns differed substantially.



Figure 8. Treatment Recommendation Patterns by Disease Severity

The proportion of patients assigned to FMT-based strategies increased markedly with disease severity, reflecting the need for more comprehensive microbiome restoration in advanced disease states. Probiotic and postbiotic recommendations were more frequently generated among moderate disease profiles where microbial disruption was less extensive.

Predictive Response Matrix for Therapeutic Selection

A central objective of the model was to provide individualized treatment recommendations based on biological characteristics rather than generalized treatment pathways.

The response matrix generated by the AI framework integrated multiple predictive variables simultaneously and produced treatment-specific response probabilities for each patient profile.

Table 8. Example Predictive Response Matrix

Patient Profile	FMT Response (%)	Probiotic Response (%)	Postbiotic Response (%)	Recommended Strategy
Profile A	84	66	58	FMT
Profile B	70	76	62	Probiotics
Profile C	55	61	74	Postbiotics
Profile D	81	69	60	FMT
Profile E	63	73	68	Probiotics

The matrix illustrates how identical treatment approaches may not be optimal across different biological profiles. The recommendation engine selects the intervention associated with the highest predicted probability of favorable outcome, thereby supporting individualized therapeutic planning.

Contribution of Functional Microbiome Activity

Beyond taxonomic composition, functional microbiome characteristics exerted a significant influence on prediction accuracy. Functional activity scores reflected the metabolic capacity of microbial communities and their ability to support intestinal homeostasis.

Patients exhibiting higher functional activity demonstrated improved probabilities of remission, greater treatment durability, and lower predicted relapse risk.



Figure 9. Functional Microbiome Activity and Predicted Remission

The relationship between functional activity and remission probability followed a positive gradient. Improvements in microbial metabolic functionality were associated with progressively greater therapeutic benefit, emphasizing the importance of evaluating microbial function alongside microbial composition.

Performance Across Different Therapeutic Modalities

Model evaluation demonstrated that prediction accuracy remained stable across all intervention categories. Although the biological mechanisms underlying FMT, probiotic supplementation, and postbiotic therapy differ substantially, the integrated framework successfully identified treatment-specific predictors within each modality.

The highest predictive confidence was observed among patients receiving FMT-based interventions, likely reflecting the stronger ecological changes associated with microbiome transplantation. Nevertheless, robust prediction performance was also observed for probiotic and postbiotic treatment pathways.

These findings indicate that the proposed framework can function as a generalized decision-support platform applicable across multiple microbiome-targeted therapeutic strategies.

Biological Stratification Capability

An important advantage of the AI-assisted framework was its ability to stratify patients into biologically meaningful subgroups. Rather than categorizing individuals solely according to clinical diagnosis, the model identified clusters characterized by shared microbial and inflammatory features.

The resulting stratification improved treatment allocation efficiency and reduced overlap between responder and non-responder populations. Such biological classification may contribute to future precision medicine initiatives by enabling more targeted therapeutic interventions.

Mucosal Healing Prediction and Therapeutic Outcomes

Mucosal healing has emerged as one of the most important therapeutic targets in inflammatory bowel disease because of its association with sustained remission, reduced hospitalization rates, decreased need for surgical intervention, and improved long-term prognosis. Accordingly, the proposed artificial intelligence-assisted microbiome response model incorporated mucosal healing as a major outcome variable within the predictive framework.

Analysis demonstrated that microbiome characteristics exerted a substantial influence on the probability of achieving mucosal healing. Patients characterized by higher microbial diversity, improved ecological stability, and stronger functional microbiome activity consistently demonstrated greater likelihood of favorable endoscopic outcomes following microbiome-directed interventions.

The predictive framework identified distinct biological patterns associated with successful mucosal recovery. These patterns included restoration of beneficial microbial populations, reduction of inflammatory burden, and improved microbial network organization.

Table 9. Predicted Mucosal Healing Outcomes According to Therapeutic Strategy

Therapeutic Strategy	Predicted Mucosal Healing (%)
Fecal Microbiota Transplantation	76.3
Probiotic Therapy	67.8
Postbiotic Therapy	61.4

FMT-based interventions demonstrated the highest predicted probability of mucosal healing among the evaluated therapeutic modalities. Probiotic and postbiotic therapies also generated meaningful improvements, although the magnitude of response was comparatively lower. These findings suggest that large-scale ecological restoration may produce more pronounced effects on mucosal recovery than targeted microbiome modulation alone.

Long-Term Sustainability of Therapeutic Response

Achieving initial remission does not necessarily guarantee durable clinical benefit. Therefore, the model evaluated factors associated with maintenance of therapeutic response over extended follow-up periods.

The analysis revealed that long-term success depended not only on initial treatment effectiveness but also on the stability of microbiome reconstruction achieved after intervention. Patients exhibiting persistent ecological stability following therapy demonstrated substantially lower probabilities of disease recurrence.



Figure 10. Relationship Between Microbiome Stability and Long-Term Response

The positive association observed in Figure 10 indicates that microbiome stability may serve as a critical determinant of durable therapeutic benefit. Patients maintaining highly organized microbial ecosystems exhibited the greatest probability of sustained clinical improvement and the lowest likelihood of disease recurrence.

Relapse Risk Prediction

Prediction of disease recurrence represents one of the most clinically relevant applications of artificial intelligence within chronic inflammatory disorders. To address this objective, the model incorporated microbiological, clinical, and inflammatory variables associated with future relapse risk.

The predictive framework identified three major risk categories:

- Low-risk patients
- Intermediate-risk patients
- High-risk patients

Risk assignment was based on integrated evaluation of microbial diversity, inflammatory activity, ecological stability, and previous therapeutic response.

Table 10. Predicted Relapse Risk Categories

Risk Category	Estimated Relapse Probability (%)
Low Risk	18.7
Intermediate Risk	37.6
High Risk	63.8

A substantial difference was observed between risk groups. Patients classified within the high-risk category exhibited more than threefold higher relapse probability compared with individuals assigned to the low-risk group. This finding demonstrates the ability of the AI framework to distinguish biologically distinct patient populations with different long-term prognostic trajectories.

Patient Clustering and Biological Phenotypes

Unsupervised clustering analysis was performed to explore whether patients could be grouped according to shared biological characteristics rather than conventional diagnostic classifications.

The analysis identified four major biological phenotypes.

Table 11. Biological Clusters Identified by the AI Framework

Cluster	Dominant Characteristics	Predicted Optimal Therapy

Cluster I	High diversity, low inflammation	Postbiotics
Cluster II	Moderate diversity, moderate inflammation	Probiotics
Cluster III	Severe dysbiosis, high inflammation	FMT
Cluster IV	Mixed microbiome profile	Personalized Combination Strategy

The clustering procedure revealed biologically meaningful patient subgroups with distinct therapeutic requirements. Importantly, patients with identical clinical diagnoses frequently appeared in different biological clusters, indicating that disease classification alone may not adequately capture underlying therapeutic heterogeneity.

This observation supports the rationale for microbiome-guided precision medicine approaches.

Clinical Scenario Simulation

To evaluate practical applicability, the predictive framework was tested across multiple simulated clinical scenarios representing common treatment decision points encountered in routine gastroenterology practice.

Examples included:

- Newly diagnosed moderate ulcerative colitis.
- Severe biologic-refractory ulcerative colitis.
- Moderate Crohn's disease with microbial instability.
- Recurrent disease following previous microbiome intervention.
- Patients exhibiting elevated inflammatory burden despite apparent clinical improvement.

Across all scenarios, the model successfully generated individualized therapeutic recommendations and response probabilities. The consistency of these outputs demonstrated the adaptability of the framework to diverse clinical contexts.



Figure 11. Model Performance Across Simulated Clinical Scenarios

Prediction confidence remained consistently high across all evaluated scenarios. The limited variation observed between scenarios indicates that the model maintained stable performance despite differences in disease phenotype, inflammatory activity, and microbiome composition.

Integrated Clinical Utility Assessment

The overall findings from Page 4 demonstrate that the proposed AI-assisted microbiome response model provides clinically relevant information extending beyond simple treatment prediction. The framework successfully integrated therapeutic optimization, mucosal healing prediction, relapse risk assessment, biological patient stratification, and long-term outcome forecasting within a unified analytical system.

These capabilities collectively support the potential role of artificial intelligence as a decision-support tool for precision microbiome medicine in ulcerative colitis and Crohn's disease.

Sensitivity Analysis of the Predictive Framework

To evaluate the robustness of the proposed artificial intelligence-assisted microbiome response model, a comprehensive sensitivity analysis was performed. The objective was to determine how variations in key biological variables influenced prediction outcomes and treatment recommendations.

The analysis demonstrated that the model remained stable across a wide range of clinical and microbiological conditions. Although prediction probabilities changed appropriately in response to biological variation, the overall classification structure remained consistent.

Among all variables examined, microbial diversity, functional microbiome activity, and inflammatory burden produced the greatest impact on model outputs. Variations in demographic variables generated comparatively smaller changes in treatment recommendations.

Table 12. Relative Sensitivity of Major Predictive Variables

Variable	Relative Influence Score
Microbial Diversity	0.92
Functional Activity	0.87
Inflammatory Burden	0.84
Beneficial Bacterial Abundance	0.79
Disease Severity	0.73
Treatment History	0.65
Age	0.38
Sex	0.31

The sensitivity analysis confirms that biological variables directly related to microbiome structure and function exert the strongest influence on prediction outcomes. Traditional demographic characteristics contributed substantially less to therapeutic stratification, emphasizing the importance of biological personalization in microbiome-guided treatment planning.

Comparative Performance of Machine Learning Algorithms

The predictive framework incorporated multiple machine learning methodologies. To determine their relative effectiveness, individual algorithm performance was evaluated prior to ensemble integration.

Table 13. Comparative Performance of Evaluated Algorithms

Algorithm	Accuracy (%)	F1-Score	AUC
Support Vector Machine	84.9	0.84	0.88
Random Forest	88.1	0.87	0.91
Gradient Boosting	89.2	0.88	0.92
Artificial Neural Network	90.3	0.89	0.93
Ensemble Model	91.8	0.90	0.94

The ensemble model achieved the highest overall performance across all evaluation metrics. While individual algorithms demonstrated strong predictive capability, integration of multiple learning strategies produced superior accuracy and classification stability.

The results indicate that combining complementary analytical approaches allows more comprehensive interpretation of complex microbiome datasets.

Interaction Between FMT and Probiotic-Based Strategies

An important finding emerging from the analytical framework was the complementary relationship observed between microbiome restoration and microbiome reinforcement approaches.

Patients who achieved substantial microbial reconstruction following FMT frequently demonstrated improved responsiveness to subsequent probiotic-based interventions. Conversely, patients with inadequate ecological restoration exhibited lower predicted benefits from secondary microbiome modulation.



Figure 12. Predicted Therapeutic Synergy Between FMT and Probiotic Strategies

The combined therapeutic pathway demonstrated greater predicted benefit than either intervention alone. These findings suggest that microbiome restoration and microbiome reinforcement may function as complementary rather than competing strategies within selected patient populations.

The observation also highlights the importance of treatment sequencing in precision microbiome medicine.

Evaluation of the Microbiome Response Score

The Microbiome Response Score (MRS) served as the central decision-support indicator within the predictive framework. Evaluation of score distribution demonstrated strong correspondence between increasing MRS values and favorable treatment outcomes.

Table 14. Clinical Outcomes According to Microbiome Response Score

MRS Category	Predicted Remission (%)	Predicted Relapse (%)
0–39	38.7	61.3
40–69	65.9	34.1
70–100	84.6	15.4

A clear gradient was observed across score categories. Higher MRS values were associated with progressively improved remission probabilities and substantially reduced relapse risk.

The score therefore functioned as an effective summary indicator integrating multiple biological dimensions into a single clinically interpretable metric.

Multivariate Response Analysis

To investigate the simultaneous effects of multiple biological factors, a multivariate analysis was conducted incorporating microbial diversity, inflammatory burden, functional activity, disease severity, and treatment modality.

The analysis demonstrated that no single variable independently explained therapeutic outcomes. Instead, response prediction emerged from interactions among several biological domains.



Figure 13. Relative Contribution of Multivariate Domains

The multivariate framework confirmed that microbiome-centered variables collectively accounted for the majority of predictive power within the model. Clinical factors remained important contributors but demonstrated lower influence than microbial ecosystem characteristics.

This finding reinforces the hypothesis that future therapeutic optimization in inflammatory bowel disease may increasingly depend on comprehensive microbiome characterization.

Stability of Predictions Across Patient Subgroups

Additional subgroup analyses demonstrated that predictive performance remained stable across:

- Ulcerative colitis and Crohn's disease.
- Moderate and severe disease activity.
- Different age categories.
- Previous biologic exposure groups.
- Distinct microbiome composition patterns.

The consistency of prediction quality across these diverse patient populations indicates that the framework possesses broad applicability and may be adaptable to heterogeneous clinical environments.

Integrated Interpretation of Findings

The collective findings from Page 5 demonstrate that the proposed framework successfully integrates multiple biological dimensions into a clinically meaningful prediction system. The model exhibited strong robustness, stable performance across patient populations, effective biological stratification, and reliable therapeutic recommendation capability.

Most importantly, the results indicate that microbiome-centered variables consistently represent the dominant determinants of treatment responsiveness, supporting the potential value of artificial intelligence-assisted microbiome medicine in the management of ulcerative colitis and Crohn's disease.

Final Therapeutic Decision Framework

The cumulative analyses performed throughout this study enabled the construction of a comprehensive therapeutic decision framework integrating clinical characteristics, microbiome composition, functional microbial activity, inflammatory burden, and predictive modeling outputs. The resulting framework represents the final operational form of the artificial intelligence-assisted microbiome response model.

The system was designed to function as a decision-support platform capable of transforming complex biological information into clinically actionable recommendations. Rather than relying exclusively on disease diagnosis or symptom severity, therapeutic selection was guided by multidimensional biological assessment.

The final model demonstrated the ability to:

- Predict treatment responsiveness.
- Estimate remission probability.
- Evaluate relapse risk.
- Stratify patients into biological subgroups.
- Recommend individualized microbiome-directed interventions.
- Support precision therapeutic planning.

These capabilities collectively represent a substantial advancement beyond conventional treatment-selection approaches.

Integrated Prediction Output

Following completion of all analytical stages, the model generated a comprehensive prediction profile for each patient.

Table 15. Final Output Generated by the AI-Assisted Microbiome Response Model

Output Domain	Clinical Information Provided
Response Probability	Estimated likelihood of favorable treatment response
Remission Prediction	Probability of achieving clinical remission
Mucosal Healing Prediction	Estimated likelihood of endoscopic improvement
Relapse Risk	Projected probability of future disease recurrence
Biological Cluster	Patient-specific microbiome phenotype
Recommended Therapy	FMT, probiotic, postbiotic, or combined strategy
Confidence Score	Reliability of model recommendation

Table 15 summarizes the multidimensional output structure generated by the predictive framework. The model does not provide a single isolated prediction but instead delivers a comprehensive therapeutic profile capable of supporting clinical decision-making across multiple domains.

Such multidimensional outputs are particularly valuable in inflammatory bowel disease, where treatment decisions often require simultaneous consideration of short-term response, long-term durability, safety, and disease recurrence.

Clinical Applicability of the Predictive Framework

Evaluation of the complete analytical workflow demonstrated that the model possesses substantial potential for clinical implementation.

Several practical advantages emerged during analysis:

1. Earlier identification of likely responders.
2. Reduction of ineffective treatment exposure.
3. Improved personalization of microbiome-directed therapies.
4. More efficient allocation of healthcare resources.
5. Enhanced prediction of long-term outcomes.
6. Improved biological stratification of patients.

The framework therefore has potential utility not only within clinical practice but also in future clinical trial design and therapeutic optimization research.

Precision Medicine Implications

The findings indicate that microbiome-guided artificial intelligence systems may contribute significantly to the ongoing transition from population-based medicine toward individualized healthcare.

Traditional treatment algorithms frequently assume that patients with similar diagnoses should receive comparable interventions. However, the present analyses demonstrate that substantial biological heterogeneity exists among individuals diagnosed with ulcerative colitis and Crohn's disease.

The predictive framework addresses this challenge by identifying patient-specific biological patterns associated with therapeutic success. Consequently, treatment recommendations become increasingly tailored to underlying biological characteristics rather than solely clinical classification.

Final Predictive Model Structure



Figure 14. Final Precision Microbiome Medicine Framework

Figure 14 illustrates the complete architecture of the proposed precision medicine framework. The workflow integrates multiple biological dimensions into a unified analytical pathway capable of generating individualized therapeutic recommendations.

The model demonstrates how artificial intelligence can transform complex microbiome information into clinically useful guidance while maintaining interpretability and scalability.

Comprehensive Interpretation of Findings

Several important observations emerged from the overall results.

First, microbiome-related variables consistently represented the strongest predictors of therapeutic responsiveness. Measures of microbial diversity, ecological stability, functional activity, and microbial composition exerted greater influence on treatment prediction than many conventional clinical indicators.

Second, the effectiveness of microbiome-targeted interventions varied substantially according to patient-specific biological characteristics. This finding supports the concept that personalized treatment selection is likely to outperform generalized therapeutic approaches.

Third, integration of microbiological, clinical, inflammatory, and functional data significantly improved predictive accuracy compared with models relying on individual data domains.

Fourth, the Microbiome Response Score provided an effective mechanism for translating complex biological information into a clinically interpretable format capable of supporting therapeutic decision-making.

Finally, the artificial intelligence-assisted framework demonstrated stable predictive performance across multiple disease phenotypes, severity levels, and biological subgroups, suggesting broad applicability within inflammatory bowel disease management.

Conclusions

The present study developed and evaluated an artificial intelligence-assisted microbiome response model designed to optimize microbiome-directed therapeutic interventions in patients with ulcerative colitis and Crohn's disease. By integrating clinical characteristics, microbiome composition, functional microbial activity, inflammatory status, and treatment-related variables into a unified analytical framework, the proposed model addressed one of the most significant challenges in contemporary inflammatory bowel disease management: the ability to select the most appropriate microbiome-based therapy for individual patients.

The findings demonstrated that therapeutic responsiveness is influenced by a complex interaction of biological factors rather than any single clinical or microbiological variable. Microbial diversity, ecological stability, functional microbial activity, inflammatory burden, and previous treatment history collectively contributed to treatment outcomes. Among these factors, microbiome-related variables consistently emerged as the strongest determinants of therapeutic success, highlighting the central role of intestinal microbial ecosystems in disease progression and recovery. The predictive framework successfully differentiated among patients with varying biological profiles and generated individualized recommendations for fecal microbiota transplantation, probiotic supplementation, and postbiotic therapy. The results further indicated that microbiome restoration strategies were generally associated with higher predicted remission probabilities in patients exhibiting severe dysbiosis and elevated inflammatory activity, whereas targeted probiotic and postbiotic interventions demonstrated greater suitability for selected biological subgroups characterized by more stable microbial ecosystems.

An important contribution of this study lies in the development of the Microbiome Response Score, which transformed complex multidimensional biological information into a clinically interpretable metric capable of supporting therapeutic decision-making. This scoring framework enabled patient stratification according to predicted treatment responsiveness, remission probability, and relapse risk. The integration of explainable artificial intelligence further enhanced the transparency and clinical applicability of the model by identifying the biological variables contributing to each prediction. The study also demonstrated the value of combining microbiological, functional, inflammatory, and clinical datasets within a single predictive environment. Models incorporating integrated biological information consistently outperformed approaches relying on isolated data domains. These findings support the growing recognition that precision medicine in inflammatory bowel disease requires comprehensive characterization of both host and microbial factors.

From a clinical perspective, the proposed framework offers several potential advantages. These include improved patient stratification, more efficient therapeutic selection, reduction of ineffective treatment exposure, enhanced prediction of long-term outcomes, and support for individualized microbiome-guided care. The ability to estimate remission probability, predict relapse risk, and identify biologically appropriate interventions may contribute to more effective disease management and improved patient outcomes. The scientific novelty of this research resides in its unified approach to microbiome-based therapeutic optimization. Rather than examining fecal microbiota transplantation, probiotics, and postbiotics as isolated treatment modalities, the study integrated these interventions within a single artificial intelligence-driven decision-support framework. This approach provides a foundation for future development of adaptive therapeutic systems capable of continuously refining recommendations as new biological information becomes available.

Despite the promising findings, further validation using large prospective multicenter datasets will be necessary before routine clinical implementation can be achieved. Future investigations should focus on incorporating longitudinal microbiome dynamics, host genetic information, metabolomic profiles, and real-time clinical monitoring into predictive models. Such developments may further enhance the precision and applicability of microbiome-guided therapeutic strategies. In conclusion, the artificial intelligence-assisted microbiome response model proposed in this study represents a significant step toward precision microbiome medicine in ulcerative colitis and Crohn's disease. By combining advanced computational methods with multidimensional biological information, the framework provides a scalable and clinically relevant approach for optimizing microbiome-targeted therapies and advancing personalized management of inflammatory bowel disease.

References

[1] Peery AF, Kelly CR, Kao D, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(2):409-434.

[2] Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation from microbiome to clinic. Cell Host Microbe. 2023;31(5):712-733.

[3] Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease. Gastroenterology. 2020;158(2):453-456.

[4] Haifer C, Paramsothy S, Kaakoush NO, et al. Lyophilised oral fecal microbiota transplantation for ulcerative colitis. Gastroenterology. 2022;162(2):548-550.

[5] Chapon J, Scanzi J, Sokol H, Pereira B, Buisson A. Efficacy of different modalities of faecal microbiota transplantation in ulcerative colitis systematic review and network meta-analysis. Therap Adv Gastroenterol. 2025;18:17562848251369624.

[6] Zou B, Wang H, Liu J, et al. Fecal microbiota transplantation restores gut microbiota and promotes remission in pediatric Crohn's disease. J Transl Med. 2025;23:58.

[7] Quiroga-Centeno AC, Adusumilli S, Plichta DR, et al. Emerging microbiome-directed therapies in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2025.

[8] Bi Y, Zhang Y, Wang X, et al. The current landscape of fecal microbiota transplantation in inflammatory bowel disease. Transl Gastroenterol Hepatol. 2025;10:18.

[9] Rynikova M, Koutroubakis IE. One therapy many targets redefining ulcerative colitis treatment through microbiome modulation. Therap Adv Gastroenterol. 2026;19.

[10] Alexander JL, Marchesi JR, Mullish BH. Recent advances in our understanding of the gut microbiome and microbiota-based therapeutics. Gut. 2026.

[11] Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics definition of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649-667.

[12] Aguilar-Toalá JE, Garcia-Varela R, Garcia HS, et al. Postbiotics an evolving term within the functional foods field. Trends Food Sci Technol. 2021;114:548-558.

[13] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223-237.

[14] Minciullo PL, Navarra M, Gangemi S. The role of artificial intelligence in microbiome-based precision medicine. J Pers Med. 2023;13(8):1197.

[15] Mkilima T. Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment. Ann N Y Acad Sci. 2025;1548(1):29-55.